{
    "data": [
        {
            "id": "4396382",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-28T02:51:45-05:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "After Gilead Sciences' Year Of Acquisitions, 2021 Is When It Becomes An Oncology Powerhouse",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "306499",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4396382-after-gilead-sciences-year-of-acquisitions-2021-is-when-becomes-oncology-powerhouse"
            }
        },
        {
            "id": "4394519",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-14T03:40:34-05:00",
                "isLockedPro": false,
                "commentCount": 103,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Continues Its Massive Acquisition Spree, Don't Miss Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304775",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4394519-gilead-sciences-continues-massive-acquisition-spree-dont-miss-out"
            }
        },
        {
            "id": "4394203",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-11T04:40:36-05:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's New Hepatitis Deal Is Enticing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304466",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4394203-gileads-new-hepatitis-deal-is-enticing"
            }
        },
        {
            "id": "4394036",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-10T09:45:35-05:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Turning 'Value Traps' Into A Dependable Payday: The Case Of Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20256",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304303",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4394036-turning-value-traps-dependable-payday-case-of-gilead"
            }
        },
        {
            "id": "4391454",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-25T05:58:00-05:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "WHO Throws Shade At Remdesivir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "302318",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4391454-who-throws-shade-remdesivir"
            }
        },
        {
            "id": "4390828",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-22T03:25:10-05:00",
                "isLockedPro": false,
                "commentCount": 122,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bye Bye Remdesivir, Hello Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "301798",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4390828-bye-bye-remdesivir-hello-gilead-sciences"
            }
        },
        {
            "id": "4389929",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-18T04:35:20-05:00",
                "isLockedPro": false,
                "commentCount": 112,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Gilded Future From Its Drug Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105497",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "300846",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4389929-gilead-gilded-future-from-drug-pipeline"
            }
        },
        {
            "id": "4389054",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-14T07:11:44-05:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Back In The Growth Game",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "300747",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4389054-gilead-sciences-back-in-growth-game"
            }
        },
        {
            "id": "4386925",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-09T05:14:52-05:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Questions Loom For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "299924",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4386925-questions-loom-for-gilead"
            }
        },
        {
            "id": "4386621",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-08T07:01:41-05:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Has The Potential To Drive Long-Term Shareholder Rewards",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "299636",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4386621-gilead-sciences-potential-to-drive-long-term-shareholder-rewards"
            }
        },
        {
            "id": "4382071",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-28T11:26:54-04:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "More Explanations Due From Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "298397",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4382071-explanations-due-from-gilead"
            }
        },
        {
            "id": "4380978",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-23T11:26:23-04:00",
                "isLockedPro": false,
                "commentCount": 116,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Real Catalysts Are Still Ahead For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "297771",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4380978-real-catalysts-are-still-ahead-for-gilead"
            }
        },
        {
            "id": "4379587",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-18T07:43:42-04:00",
                "isLockedPro": false,
                "commentCount": 166,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: 'Failed' Remdesivir Solidarity Study Might Really Show Efficacy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "296943",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4379587-gilead-failed-remdesivir-solidarity-study-might-really-show-efficacy"
            }
        },
        {
            "id": "4379021",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-14T10:50:07-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Incredible Antivirals, Risky Drug Lineup",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105636",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293529",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4379021-gilead-incredible-antivirals-risky-drug-lineup"
            }
        },
        {
            "id": "4377292",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-02T01:53:14-04:00",
                "isLockedPro": false,
                "commentCount": 108,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Cancer Follies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293014",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4377292-gileads-cancer-follies"
            }
        },
        {
            "id": "4376471",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-26T08:30:20-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Makes A Sizeable Bet On Immunomedics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293882",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4376471-gilead-makes-sizeable-bet-on-immunomedics"
            }
        },
        {
            "id": "4376270",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-25T04:02:00-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Debt Fueled Bottom",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "293868",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4376270-gilead-sciences-debt-fueled-bottom"
            }
        },
        {
            "id": "4374472",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-15T14:58:53-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Markets Like Deal For Immunomedics, And I Agree",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292497",
                            "type": "sentiment"
                        },
                        {
                            "id": "292510",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374472-gilead-markets-like-deal-for-immunomedics-and-i-agree"
            }
        },
        {
            "id": "4374232",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-14T16:47:07-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Gilead's $21 Billion Oncology Bet Means For Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292332",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374232-what-gileads-21-billion-oncology-bet-means-for-investors"
            }
        },
        {
            "id": "4374161",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-14T13:23:45-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences And Immunomedics: Buy Post-Market Reaction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292265",
                            "type": "sentiment"
                        },
                        {
                            "id": "292358",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374161-gilead-sciences-and-immunomedics-buy-post-market-reaction"
            }
        },
        {
            "id": "4372548",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-04T00:54:37-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Humira Battles: AbbVie's Upa Versus Gilead's Filgo-Redux",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289929",
                            "type": "sentiment"
                        },
                        {
                            "id": "289930",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4372548-humira-battles-abbvies-upa-versus-gileads-filgo-redux"
            }
        },
        {
            "id": "4371155",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-27T14:09:33-04:00",
                "isLockedPro": false,
                "commentCount": 125,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID-19 Treatments: Remdesivir Disappoints, Antiviral SPL7013 And Monoclonal Antibodies Interesting For Prevention/Early-Stage Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290110",
                            "type": "sentiment"
                        },
                        {
                            "id": "290111",
                            "type": "sentiment"
                        },
                        {
                            "id": "290112",
                            "type": "sentiment"
                        },
                        {
                            "id": "290113",
                            "type": "sentiment"
                        },
                        {
                            "id": "290075",
                            "type": "sentiment"
                        },
                        {
                            "id": "290076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4371155-covidminus-19-treatments-remdesivir-disappoints-antiviral-spl7013-and-monoclonal-antibodies"
            }
        },
        {
            "id": "4370247",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-22T07:24:19-04:00",
                "isLockedPro": false,
                "commentCount": 104,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Market Neutral Strategy: Long AbbVie, Short Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289255",
                            "type": "sentiment"
                        },
                        {
                            "id": "289256",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4370247-market-neutral-strategy-long-abbvie-short-gilead"
            }
        },
        {
            "id": "4370130",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-21T10:59:41-04:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "An Issue Presents A Buying Opportunity For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289209",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4370130-issue-presents-buying-opportunity-for-gilead"
            }
        },
        {
            "id": "4369900",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-20T09:52:01-04:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Fails At Filgotinib - What's Next?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289034",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4369900-gilead-sciences-fails-filgotinib-next"
            }
        },
        {
            "id": "4364063",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-04T04:37:09-04:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences - Now That The COVID-19 Hype Is Over, Take A Look",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286783",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4364063-gilead-sciences-now-covidminus-19-hype-is-over-take-look"
            }
        },
        {
            "id": "4363942",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-03T17:16:03-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Remdesivir Remains A Distraction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286679",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4363942-gilead-sciences-remdesivir-remains-distraction"
            }
        },
        {
            "id": "4363620",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-02T11:20:57-04:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Perhaps A Value Trap No Longer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286491",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4363620-gilead-perhaps-value-trap-no-longer"
            }
        },
        {
            "id": "4363002",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-31T13:48:22-04:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Buy And Hold",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286400",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4363002-gilead-sciences-buy-and-hold"
            }
        },
        {
            "id": "4362359",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-30T12:03:22-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Upside From Remdesivir May Be Priced In",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286220",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4362359-gilead-upside-from-remdesivir-may-be-priced-in"
            }
        },
        {
            "id": "4360947",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-27T09:00:36-04:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: 2 Upcoming Catalysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "285675",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4360947-gilead-2-upcoming-catalysts"
            }
        },
        {
            "id": "4359822",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-22T08:06:47-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Remdesivir Is Not The Only Reason To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105446",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "284967",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4359822-gilead-remdesivir-is-not-only-reason-to-buy"
            }
        },
        {
            "id": "4358249",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-13T18:24:41-04:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Remdesivir Reduces Mortality Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "283734",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4358249-gilead-remdesivir-reduces-mortality-risk"
            }
        },
        {
            "id": "4357550",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-08T14:40:46-04:00",
                "isLockedPro": false,
                "commentCount": 241,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: No Benefit From Remdesivir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "283166",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4357550-gilead-sciences-no-benefit-from-remdesivir"
            }
        },
        {
            "id": "4356709",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-02T08:22:19-04:00",
                "isLockedPro": false,
                "commentCount": 147,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Remdesivir Sold Out Already",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "282362",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356709-gileads-remdesivir-sold-out-already"
            }
        },
        {
            "id": "4356184",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-29T12:06:25-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Pricing Remdesivir At $2,340 Per Patient",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281920",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356184-gilead-pricing-remdesivir-2340-per-patient"
            }
        },
        {
            "id": "4356168",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-29T10:42:37-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Finally Delivers On Remdesivir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281913",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4356168-gilead-finally-delivers-on-remdesivir"
            }
        },
        {
            "id": "4355860",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-26T12:35:56-04:00",
                "isLockedPro": false,
                "commentCount": 106,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Analysts Underestimate Gilead COVID-19 Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281580",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4355860-analysts-underestimate-gilead-covidminus-19-treatment"
            }
        },
        {
            "id": "4355095",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-22T22:57:46-04:00",
                "isLockedPro": false,
                "commentCount": 127,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Remdesivir To Miss End Stage COVID-19 Market, But It Doesn't Matter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "280952",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4355095-gileads-remdesivir-to-miss-end-stage-covidminus-19-market-doesnt-matter"
            }
        },
        {
            "id": "4355083",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-22T20:14:22-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Remdesivir Update",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "280810",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4355083-gilead-remdesivir-update"
            }
        },
        {
            "id": "4354790",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-20T07:04:19-04:00",
                "isLockedPro": false,
                "commentCount": 360,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vaccines Will Underwhelm, And Why Gilead Has A Substantially Larger Market Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105467",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "280466",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4354790-vaccines-will-underwhelm-and-why-gilead-substantially-larger-market-opportunity"
            }
        },
        {
            "id": "4353206",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-10T22:02:45-04:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Great Addition To A Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105705",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "278931",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4353206-gilead-sciences-great-addition-to-dividend-growth-portfolio"
            }
        },
        {
            "id": "4352910",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-09T17:42:34-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rumored Gilead-AstraZeneca Tie-Up Wouldn't Make Much Sense",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105568",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "279191",
                            "type": "sentiment"
                        },
                        {
                            "id": "279192",
                            "type": "sentiment"
                        },
                        {
                            "id": "279193",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4352910-rumored-gilead-astrazeneca-tie-up-wouldnt-make-much-sense"
            }
        },
        {
            "id": "4352717",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-09T03:27:04-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AstraZeneca And Gilead Sciences Merger Rumors - Something To Watch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "278973",
                            "type": "sentiment"
                        },
                        {
                            "id": "278974",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4352717-astrazeneca-and-gilead-sciences-merger-rumors-something-to-watch"
            }
        },
        {
            "id": "4352097",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-04T23:06:56-04:00",
                "isLockedPro": false,
                "commentCount": 410,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID-19: Gilead's Remdesivir Might Be As Good As It Gets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "278528",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4352097-covidminus-19-gileads-remdesivir-might-be-good-gets"
            }
        },
        {
            "id": "4350568",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-28T12:03:07-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences - The Overall Portfolio Has Never Been This Strong",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "277396",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4350568-gilead-sciences-overall-portfolio-never-this-strong"
            }
        },
        {
            "id": "4349833",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-25T01:26:07-04:00",
                "isLockedPro": false,
                "commentCount": 270,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "NIH Study Supports Wide Use Of Gilead's Remdesivir In COVID-19",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276847",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4349833-nih-study-supports-wide-use-of-gileads-remdesivir-in-covidminus-19"
            }
        },
        {
            "id": "4349386",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-21T15:04:31-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And Galapagos: Filgotinib Ulcerative Colitis Trial Review",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56062",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276491",
                            "type": "sentiment"
                        },
                        {
                            "id": "276492",
                            "type": "sentiment"
                        },
                        {
                            "id": "276493",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4349386-gilead-and-galapagos-filgotinib-ulcerative-colitis-trial-review"
            }
        },
        {
            "id": "4349312",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-21T12:20:12-04:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Declines May Have Only Started",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276568",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4349312-gileads-declines-may-only-started"
            }
        },
        {
            "id": "4345897",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-11T02:38:31-04:00",
                "isLockedPro": false,
                "commentCount": 108,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Strategic Update - Focus On 'Defend/Extend' HIV Franchise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274819",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4345897-gilead-strategic-update-focus-on-defend-extend-hiv-franchise"
            }
        },
        {
            "id": "4344116",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-07T11:49:41-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Even After FDA Approval Market Keeps Underestimating Gilead's Antiviral",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274259",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4344116-even-after-fda-approval-market-keeps-underestimating-gileads-antiviral"
            }
        },
        {
            "id": "4343983",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-07T04:55:57-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Rapidly Building Up One Of The World's Best-Recognized Brands",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274131",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4343983-gilead-sciences-rapidly-building-up-one-of-worlds-best-recognized-brands"
            }
        },
        {
            "id": "4343824",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-06T18:46:15-04:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Change From Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274149",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4343824-change-from-gilead"
            }
        },
        {
            "id": "4343810",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-06T17:14:22-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Breaking Bio: Drug Makers Cooking Off March Lows (Video)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274115",
                            "type": "sentiment"
                        },
                        {
                            "id": "274116",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4343810-breaking-bio-drug-makers-cooking-off-march-lows-video"
            }
        },
        {
            "id": "4342726",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-04T12:14:23-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Adam Feuerstein Talks COVID-19 Treatments And Vaccines On Alpha Trader (Podcast Transcript)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105447",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4342726-adam-feuerstein-talks-covidminus-19-treatments-and-vaccines-on-alpha-trader-podcast"
            }
        },
        {
            "id": "4342715",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-04T11:28:27-04:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead Can't Exit The Current Trading Range",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273720",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342715-why-gilead-cant-exit-current-trading-range"
            }
        },
        {
            "id": "4342565",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-04T01:11:21-04:00",
                "isLockedPro": false,
                "commentCount": 107,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Reports (Part 1): Focus On Remdesivir For COVID-19",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273511",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4342565-gilead-reports-part-1-focus-on-remdesivir-for-covidminus-19"
            }
        },
        {
            "id": "4342366",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-02T16:12:09-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Still A Core Holding",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273448",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342366-gilead-sciences-still-core-holding"
            }
        },
        {
            "id": "4342317",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-02T11:01:55-04:00",
                "isLockedPro": false,
                "commentCount": 201,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Why I'm Buying More",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273431",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342317-gilead-why-buying"
            }
        },
        {
            "id": "4342218",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-01T19:03:54-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: COVID-19 Effective Control Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273154",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342218-gilead-sciences-covidminus-19-effective-control-potential"
            }
        },
        {
            "id": "4342197",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-01T18:32:48-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Despite Its Recent Surge, The Stock Did Not Reach Its Fair Value Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105409",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273324",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342197-gilead-despite-recent-surge-stock-not-reach-fair-value-yet"
            }
        },
        {
            "id": "4342114",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-01T15:13:39-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Has A Lot More Explaining To Do",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273386",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342114-gilead-lot-explaining-to"
            }
        },
        {
            "id": "4341195",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-29T18:10:12-04:00",
                "isLockedPro": false,
                "commentCount": 203,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Has A Lot Of Explaining To Do Thursday",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "272978",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4341195-gilead-lot-of-explaining-to-thursday"
            }
        },
        {
            "id": "4341189",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-29T17:30:27-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: SIMPLE Trial Indicates Remdesivir May Help Severely Ill COVID-19 Patients",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273004",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4341189-gilead-simple-trial-indicates-remdesivir-may-help-severely-ill-covidminus-19-patients"
            }
        },
        {
            "id": "4340366",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-28T11:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Adam Feuerstein Talks COVID-19 Treatments And Vaccines On Alpha Trader",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105447",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4340366-adam-feuerstein-talks-covidminus-19-treatments-and-vaccines-on-alpha-trader"
            }
        },
        {
            "id": "4339840",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-24T13:32:39-04:00",
                "isLockedPro": false,
                "commentCount": 105,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Why Remdesivir Won't Be A Magic Bullet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56062",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271574",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4339840-gilead-why-remdesivir-wont-be-magic-bullet"
            }
        },
        {
            "id": "4339620",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-23T18:08:52-04:00",
                "isLockedPro": false,
                "commentCount": 110,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Next Shoe To Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271597",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4339620-gilead-next-shoe-to-drop"
            }
        },
        {
            "id": "4338522",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-20T10:06:14-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: A Good Bet Either Way",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271207",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338522-gilead-good-bet-either-way"
            }
        },
        {
            "id": "4338489",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-20T08:22:15-04:00",
                "isLockedPro": false,
                "commentCount": 122,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: New Remdesivir Data Set Up A Potential Short Trade",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270980",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338489-gilead-new-remdesivir-data-set-up-potential-short-trade"
            }
        },
        {
            "id": "4338431",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-19T20:04:30-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Speculator's View On Gilead Sciences And Its Hopes To Treat The Coronavirus Pandemic",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21950",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271188",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338431-speculators-view-on-gilead-sciences-and-hopes-to-treat-coronavirus-pandemic"
            }
        },
        {
            "id": "4338430",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-19T19:57:52-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead, Remdesivir, COVID-19 And Political Risk",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24643",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271069",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338430-gilead-remdesivir-covidminus-19-and-political-risk"
            }
        },
        {
            "id": "4338423",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-19T17:06:08-04:00",
                "isLockedPro": false,
                "commentCount": 1129,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead's COVID Drug May Be The Magic Bullet We Need",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "271056",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4338423-why-gileads-covid-drug-may-be-magic-bullet-need"
            }
        },
        {
            "id": "4338314",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-17T21:34:28-04:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Gauging The Potential Of Remdesivir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270890",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338314-gilead-sciences-gauging-potential-of-remdesivir"
            }
        },
        {
            "id": "4338198",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-17T10:21:39-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Someone Was Betting Big On Gilead On April 16",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270927",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338198-someone-was-betting-big-on-gilead-on-april-16"
            }
        },
        {
            "id": "4338141",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-17T03:32:57-04:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "STAT Obtained Data Indicates COVID-19 Treatment Potentially Effective",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338141-stat-obtained-data-indicates-covidminus-19-treatment-potentially-effective"
            }
        },
        {
            "id": "4337597",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-14T18:10:49-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Analyzing Remdesivir's Potential In A Difficult Time",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270372",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4337597-gilead-sciences-analyzing-remdesivirs-potential-in-difficult-time"
            }
        },
        {
            "id": "4337518",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-14T12:34:00-04:00",
                "isLockedPro": false,
                "commentCount": 56,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: New Study Of Remdesivir Shows Promise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269841",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4337518-gilead-new-study-of-remdesivir-shows-promise"
            }
        },
        {
            "id": "4336701",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-08T14:25:28-04:00",
                "isLockedPro": false,
                "commentCount": 89,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Upside From Potential Coronavirus Treatment Could Dissipate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269403",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4336701-gilead-upside-from-potential-coronavirus-treatment-dissipate"
            }
        },
        {
            "id": "4336574",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-08T01:59:31-04:00",
                "isLockedPro": false,
                "commentCount": 375,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Has There Been A Clue On Gilead's Remdesivir?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269311",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4336574-clue-on-gileads-remdesivir"
            }
        },
        {
            "id": "4336516",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-07T16:06:09-04:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Path To COVID-19 Market Dominance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105619",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "268264",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4336516-gileads-path-to-covidminus-19-market-dominance"
            }
        }
    ]
}